Rituximab in CD20 Positive Multiple Myeloma

Leukemia- United Kingdom

doi 10.1038/sj.leu.2405010

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

Two Structurally Different Rituximab-Specific CD20 Mimotope Peptides Reveal That Rituximab Recognizes Two Different CD20-Associated Epitopes

Journal of Immunology
AllergyImmunology
2008English

Enhanced Expression of FCER1G Predicts Positive Prognosis in Multiple Myeloma

Journal of Cancer
Oncology
2020English

MYEOV (Myeloma Overexpressed (In a Subset of T(11;14) Positive Multiple Myelomas))

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2012English

B Cell Therapy for Rheumatoid Arthritis: The Rituximab (Anti-Cd20) Experience

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2003English

Multiple Myeloma

Annals of Internal Medicine
Internal MedicineMedicine
1942English

Multiple Myeloma

Bone Marrow Transplantation
TransplantationHematology
2000English

Multiple Myeloma

Cancer Imaging
Nuclear MedicineRadiologyUltrasound TechnologyOncologyRadiologicalImagingMedicine
2004English

Regulation of CD20 in Rituximab-Resistant Cell Lines and B-Cell Non-Hodgkin Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2012English

Editorial: Immunotherapy in Multiple Myeloma

Frontiers in Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy